New owner for GL Chemtec
Edgewater Capital Partners, a lower middle-market private equity firm which has made previous investments in life Sciences and pharma services, has acquired GL Chemtec of Oakville, Ontario, a CRO which offers chemistry R&D and scale-up services to support API development, plus advanced materials for drug delivery, medical devices and other life science applications. No financial details were disclosed.
GLC, Edgewater stated, “is uniquely positioned within the North American market to address the growing need for advanced chemistry services with a focus on speed, flexibility and high customer-touch business model”. The firm has an innovation centre where it provides R&D services supporting advanced multi-step organic synthesis of next-generation therapies, and a new facility housing a scale-up lab, two pilot plant suites and a material science laboratory, including cleanrooms for advanced material development.